These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 10137800)

  • 1. Who cares what it costs to dispense a Medicaid prescription?
    Lamphere-Thorpe JA; Johnston WP; Kilpatrick KE; Norwood GJ
    Health Care Financ Rev; 1994; 15(3):9-24. PubMed ID: 10137800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. State Medicaid pharmacy payments and their relation to estimated costs.
    Adams EK; Kreling DH; Gondek K
    Health Care Financ Rev; 1994; 15(3):25-42. PubMed ID: 10137796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association of insurance type with costs of dispensed drugs.
    Mott DA; Kreling DH
    Inquiry; 1998; 35(1):23-35. PubMed ID: 9597015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of costs to dispense prescriptions in independently owned, closed-door long-term care pharmacies.
    Carroll NV; Rupp MT; Holdford DA
    J Manag Care Spec Pharm; 2014 Mar; 20(3):291-300. PubMed ID: 24564809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost and price of comparable branded and generic pharmaceuticals.
    Bloom BS; Wierz DJ; Pauly MV
    JAMA; 1986 Nov; 256(18):2523-30. PubMed ID: 3773152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug utilization and cost in a Medicaid population: a simulation study of community vs. mail order pharmacy.
    Valluri S; Seoane-Vazquez E; Rodriguez-Monguio R; Szeinbach SL
    BMC Health Serv Res; 2007 Jul; 7():122. PubMed ID: 17663768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. State and federal government mandates are changing the face of pharmacy management.
    Giaquinta D
    Manag Care Interface; 2001 May; 14(5):50-2. PubMed ID: 11385948
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacist and physician satisfaction and rates of switching to preferred medications associated with an instant prior authorization program for proton pump inhibitors in the North Carolina Medicaid program.
    Jacobson Vann JC; Christofferson S; Humble CG; Wegner SE; Feaganes JR; Trygstad TK
    J Manag Care Pharm; 2010 May; 16(4):250-63. PubMed ID: 20433216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Financial impact of patients enrolled in a medication adherence program at an independent community pharmacy.
    Clifton CL; Branham AR; Hayes HH; Moose JS; Rhodes LA; Marciniak MW
    J Am Pharm Assoc (2003); 2018; 58(4S):S109-S113. PubMed ID: 30006182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating pharmacy level prescription drug acquisition costs for third-party reimbursement.
    Kreling DH; Kirk KW
    Med Care; 1986 Jul; 24(7):590-600. PubMed ID: 3523065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicaid policies for HIV-related prescription drugs.
    Buchanan RJ; Smith SR
    Health Care Financ Rev; 1994; 15(3):43-61. PubMed ID: 10137797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Savings from Canadian Internet pharmacies are limited.
    Rothberg M
    Ann Intern Med; 2006 Feb; 144(3):224; author reply 224-5. PubMed ID: 16461977
    [No Abstract]   [Full Text] [Related]  

  • 13. Copayment for pharmaceutical services in a Medicaid program.
    Nelson AA; Quick MR
    Contemp Pharm Pract; 1980; 3(1):37-42. PubMed ID: 10297666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient counseling in community pharmacy and its relationship with prescription payment methods and practice settings.
    Raisch DW
    Ann Pharmacother; 1993 Oct; 27(10):1173-9. PubMed ID: 8251681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study of the additional costs of dispensing workers' compensation prescriptions.
    Schafermeyer KW
    Res Social Adm Pharm; 2007 Mar; 3(1):123-36. PubMed ID: 17350561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Third-party reimbursement for generic prescription drugs: The prevalence of below-cost reimbursement in an environment of maximum allowable cost-based reimbursement.
    Murry L; Gerleman B; Urick B; Urmie J
    J Am Pharm Assoc (2003); 2018; 58(4):421-425. PubMed ID: 29861152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacy Benefit Manager Market Concentration for Prescriptions Filled at US Retail Pharmacies.
    Qato DM; Chen Y; Van Nuys K
    JAMA; 2024 Oct; 332(15):1298-1299. PubMed ID: 39255301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Store and prescription characteristics associated with primary medication nonadherence.
    Jackson TH; Bentley JP; McCaffrey DJ; Pace P; Holmes E; West-Strum D
    J Manag Care Spec Pharm; 2014 Aug; 20(8):824-32. PubMed ID: 25062076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating a reasonable reimbursement for community pharmacies in third-party programs.
    Carroll NV
    Manag Care Interface; 1999 Feb; 12(2):73-6, 79-80. PubMed ID: 10346189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing potential prescription reimbursement changes: estimated acquisition costs in Wisconsin.
    Kreling DH
    Health Care Financ Rev; 1989; 10(3):67-75. PubMed ID: 10313098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.